151 related articles for article (PubMed ID: 37165841)
1. A novel approach to overcome drug resistance in acute myeloid leukemia.
Mazewski C; Platanias LC
Haematologica; 2023 Nov; 108(11):2889-2890. PubMed ID: 37165841
[No Abstract] [Full Text] [Related]
2. Personalized therapy for acute myeloid leukemia.
Hourigan CS; Karp JE
Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
[TBL] [Abstract][Full Text] [Related]
3. Letting microRNAs overcome resistance to chemotherapy in acute myeloid leukemia.
Sakamoto KM
Leuk Lymphoma; 2014 Jul; 55(7):1449-50. PubMed ID: 24206095
[No Abstract] [Full Text] [Related]
4. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.
Palaiologou D; Panayiotidis P; Papanikolaou G; Georgiou G; Boutsikas G; Hatzinicolaou SL; Pangalis GA; Sakellaropoulos N; Vassilakopoulos TP; Angelopoulou MK
Int J Lab Hematol; 2015 Feb; 37(1):e7-e10. PubMed ID: 24809224
[No Abstract] [Full Text] [Related]
5. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
6. INPP4B, a new player in the chemoresistance of AML.
Recher C
Blood; 2015 Apr; 125(18):2738-9. PubMed ID: 25931577
[No Abstract] [Full Text] [Related]
7. Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia.
Izadirad M; Jafari L; James AR; Unfried JP; Wu ZX; Chen ZS
Drug Discov Today; 2021 Jul; 26(7):1735-1743. PubMed ID: 33781951
[TBL] [Abstract][Full Text] [Related]
8. miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia.
Krakowsky RHE; Wurm AA; Gerloff D; Katzerke C; Bräuer-Hartmann D; Hartmann JU; Wilke F; Thiede C; Müller-Tidow C; Niederwieser D; Behre G
Blood Cancer J; 2018 Mar; 8(3):36. PubMed ID: 29563490
[No Abstract] [Full Text] [Related]
9. MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells.
Dai CW; Bai QW; Zhang GS; Cao YX; Shen JK; Pei MF; Yin CC
Leuk Lymphoma; 2014 Jul; 55(7):1645-8. PubMed ID: 24067109
[No Abstract] [Full Text] [Related]
10. In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene.
Such E; Cordón L; Sempere A; Villamón E; Ibañez M; Luna I; Gómez-Seguí I; López-Pavía M; Alonso C; Lo-Coco F; Cervera J; Sanz MA
Ann Hematol; 2014 Nov; 93(11):1931-3. PubMed ID: 24728721
[No Abstract] [Full Text] [Related]
11. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
Portell CA; Sekeres MA; Rogers HJ; Tiu RV
Br J Haematol; 2012 Apr; 157(2):266-7. PubMed ID: 22150289
[No Abstract] [Full Text] [Related]
12. Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.
Zebisch A; Hatzl S; Pichler M; Wölfler A; Sill H
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973410
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.
Walter RB; Othus M; Paietta EM; Racevskis J; Fernandez HF; Lee JW; Sun Z; Tallman MS; Patel J; Gönen M; Abdel-Wahab O; Levine RL; Estey EH
Leukemia; 2015 Oct; 29(10):2104-7. PubMed ID: 25772026
[No Abstract] [Full Text] [Related]
14. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
[TBL] [Abstract][Full Text] [Related]
15. Long-arm deletions in chromosome 6 in acute myelogenous leukemia: update on two cases.
Sundareshan TS; Lakshmi Devi V; Madhumathi DS; Appaji L; Girish MH; Prabhash K; Bapsy PP
Cancer Genet Cytogenet; 2004 Oct; 154(1):93-5. PubMed ID: 15381383
[No Abstract] [Full Text] [Related]
16. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
[No Abstract] [Full Text] [Related]
17. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
18. Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia.
Zhan D; Zhang Y; Xiao P; Zheng X; Ruan M; Zhang J; Chen A; Zou Y; Chen Y; Huang G; Hu S; Wang QF; Zhu X
Leuk Res; 2018 Feb; 65():20-24. PubMed ID: 29253671
[TBL] [Abstract][Full Text] [Related]
19. Phosphoproteomics profiling reveals a kinase network conferring acute myeloid leukaemia intrinsic chemoresistance and indicates HMGA1 phosphorylation as a potential influencer.
Zhu Y; He X; Li S; Gan Y; Li Z; Wang H; Dong H; Zhang L; Xue SL; Xu Y; Li L
Clin Transl Med; 2022 Mar; 12(3):e749. PubMed ID: 35297189
[No Abstract] [Full Text] [Related]
20. [Inhibition of NF-kB Activation Decreases Resistance in Acute Myeloid Leukemia Cells to TRAIL-induced Apoptosis in Multicellular Aggregates].
Fadeev RS; Solovieva ME; Slyadovskiy DA; Zakharov SG; Fadeeva IS; Senotov AS; Golenkov AK; Akatov VS
Biofizika; 2015; 60(6):1146-50. PubMed ID: 26841509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
